Which has preferable valuation & earnings, STIM or NYXH?

Neuronetics has higher revenue and earnings than Nyxoah. Neuronetics is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $149.16M 1.47 -$39M -$0.44 N/A Nyxoah $11.33M 4.55 -$101.92M -$2.52 N/A

Is STIM or NYXH more profitable?

Neuronetics has a net margin of -19.62% compared to Nyxoah's net margin of -443.16%. Neuronetics' return on equity of -125.11% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% Nyxoah -443.16% -178.90% -81.83%

Does the media refer more to STIM or NYXH?

In the previous week, Nyxoah had 1 more articles in the media than Neuronetics. MarketBeat recorded 3 mentions for Nyxoah and 2 mentions for Neuronetics. Neuronetics' average media sentiment score of 0.00 equaled Nyxoah'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, NYXH or ELMD?

Electromed has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $11.33M 4.55 -$101.92M -$2.52 N/A Electromed $73.78M 3.13 $5.15M $1.31 21.05

Is NYXH or ELMD more profitable?

Electromed has a net margin of 11.34% compared to Nyxoah's net margin of -443.16%. Electromed's return on equity of 15.71% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -443.16% -178.90% -81.83% Electromed 11.34% 15.71% 13.37%

Which has stronger valuation & earnings, PDEX or NYXH?

Pro-Dex has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $77.55M 2.97 $13.66M $4.13 17.42 Nyxoah $11.33M 4.55 -$101.92M -$2.52 N/A

Is PDEX or NYXH more profitable?

Pro-Dex has a net margin of 17.62% compared to Nyxoah's net margin of -443.16%. Pro-Dex's return on equity of 25.13% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 17.62% 25.13% 16.02% Nyxoah -443.16% -178.90% -81.83%

Does the media prefer PDEX or NYXH?

In the previous week, Pro-Dex had 3 more articles in the media than Nyxoah. MarketBeat recorded 6 mentions for Pro-Dex and 3 mentions for Nyxoah. Pro-Dex's average media sentiment score of 1.09 beat Nyxoah's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nyxoah 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, NYXH or PROF?

Profound Medical has higher revenue and earnings than Nyxoah. Profound Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $11.33M 4.55 -$101.92M -$2.52 N/A Profound Medical $19.09M 10.99 -$42.57M -$0.98 N/A

Is NYXH or PROF more profitable?

Profound Medical has a net margin of -171.57% compared to Nyxoah's net margin of -443.16%. Profound Medical's return on equity of -63.03% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -443.16% -178.90% -81.83% Profound Medical -171.57% -63.03% -51.24%

Do analysts rate NYXH or ZJYL?

Nyxoah currently has a consensus price target of $4.26, suggesting a potential upside of 220.45%. Given Nyxoah's stronger consensus rating and higher probable upside, research analysts clearly believe Nyxoah is more favorable than Jin Medical International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nyxoah 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Jin Medical International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, NYXH or ZJYL?

Jin Medical International has higher revenue and earnings than Nyxoah. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $11.33M 4.55 -$101.92M -$2.52 N/A Jin Medical International $20.69M 7.77 $1.19M N/A N/A

Nyxoah (NYXH) Competitors

$1.33 -0.07 (-5.00%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.33 0.00 (-0.30%)

As of 06:24 AM Eastern

Compare

NYXH vs. STIM, ELMD, PDEX, PROF, and ZJYL

Should you buy Nyxoah stock or one of its competitors? Nyxoah's main competitors and comparable companies include Neuronetics (STIM), Electromed (ELMD), Pro-Dex (PDEX), Profound Medical (PROF), and Jin Medical International (ZJYL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nyxoah compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Neuronetics presently has a consensus price target of $4.67, indicating a potential upside of 62.04%. Nyxoah has a consensus price target of $4.26, indicating a potential upside of 220.45%. Given Nyxoah's higher probable upside, analysts clearly believe Nyxoah is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Neuronetics has higher revenue and earnings than Nyxoah. Neuronetics is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.47	-$39M	-$0.44	N/A
Nyxoah	$11.33M	4.55	-$101.92M	-$2.52	N/A

Neuronetics has a net margin of -19.62% compared to Nyxoah's net margin of -443.16%. Neuronetics' return on equity of -125.11% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
Nyxoah	-443.16%	-178.90%	-81.83%

53.6% of Neuronetics shares are held by institutional investors. 8.4% of Neuronetics shares are held by company insiders. Comparatively, 17.1% of Nyxoah shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Nyxoah had 1 more articles in the media than Neuronetics. MarketBeat recorded 3 mentions for Nyxoah and 2 mentions for Neuronetics. Neuronetics' average media sentiment score of 0.00 equaled Nyxoah'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neuronetics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Nyxoah has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Summary

Neuronetics beats Nyxoah on 9 of the 15 factors compared between the two stocks.

How does Nyxoah compare to Electromed?

Nyxoah (NASDAQ:NYXH) and Electromed (NYSE:ELMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

40.8% of Electromed shares are held by institutional investors. 17.1% of Nyxoah shares are held by company insiders. Comparatively, 10.5% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Electromed has a net margin of 11.34% compared to Nyxoah's net margin of -443.16%. Electromed's return on equity of 15.71% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
Electromed	11.34%	15.71%	13.37%

Nyxoah currently has a consensus target price of $4.26, suggesting a potential upside of 220.45%. Electromed has a consensus target price of $43.75, suggesting a potential upside of 58.69%. Given Nyxoah's higher probable upside, equities research analysts plainly believe Nyxoah is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Nyxoah has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Electromed has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Electromed has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	4.55	-$101.92M	-$2.52	N/A
Electromed	$73.78M	3.13	$5.15M	$1.31	21.05

In the previous week, Nyxoah had 3 more articles in the media than Electromed. MarketBeat recorded 3 mentions for Nyxoah and 0 mentions for Electromed. Nyxoah's average media sentiment score of 0.00 equaled Electromed'saverage media sentiment score.

Company	Overall Sentiment
Nyxoah	Neutral
Electromed	Neutral

Summary

Electromed beats Nyxoah on 10 of the 15 factors compared between the two stocks.

How does Nyxoah compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Pro-Dex presently has a consensus target price of $74.00, suggesting a potential upside of 2.86%. Nyxoah has a consensus target price of $4.26, suggesting a potential upside of 220.45%. Given Nyxoah's higher possible upside, analysts clearly believe Nyxoah is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Pro-Dex has a net margin of 17.62% compared to Nyxoah's net margin of -443.16%. Pro-Dex's return on equity of 25.13% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	17.62%	25.13%	16.02%
Nyxoah	-443.16%	-178.90%	-81.83%

Pro-Dex has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market. Comparatively, Nyxoah has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

In the previous week, Pro-Dex had 3 more articles in the media than Nyxoah. MarketBeat recorded 6 mentions for Pro-Dex and 3 mentions for Nyxoah. Pro-Dex's average media sentiment score of 1.09 beat Nyxoah's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.3% of Pro-Dex shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pro-Dex has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$77.55M	2.97	$13.66M	$4.13	17.42
Nyxoah	$11.33M	4.55	-$101.92M	-$2.52	N/A

Summary

Pro-Dex beats Nyxoah on 13 of the 17 factors compared between the two stocks.

How does Nyxoah compare to Profound Medical?

Nyxoah (NASDAQ:NYXH) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

47.9% of Profound Medical shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nyxoah has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

In the previous week, Nyxoah had 3 more articles in the media than Profound Medical. MarketBeat recorded 3 mentions for Nyxoah and 0 mentions for Profound Medical. Nyxoah's average media sentiment score of 0.00 equaled Profound Medical'saverage media sentiment score.

Company	Overall Sentiment
Nyxoah	Neutral
Profound Medical	Neutral

Nyxoah currently has a consensus target price of $4.26, suggesting a potential upside of 220.45%. Profound Medical has a consensus target price of $11.50, suggesting a potential upside of 100.35%. Given Nyxoah's higher probable upside, equities research analysts clearly believe Nyxoah is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Profound Medical has a net margin of -171.57% compared to Nyxoah's net margin of -443.16%. Profound Medical's return on equity of -63.03% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
Profound Medical	-171.57%	-63.03%	-51.24%

Profound Medical has higher revenue and earnings than Nyxoah. Profound Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	4.55	-$101.92M	-$2.52	N/A
Profound Medical	$19.09M	10.99	-$42.57M	-$0.98	N/A

Summary

Profound Medical beats Nyxoah on 10 of the 16 factors compared between the two stocks.

How does Nyxoah compare to Jin Medical International?

Nyxoah (NASDAQ:NYXH) and Jin Medical International (NASDAQ:ZJYL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Jin Medical International has a net margin of 0.00% compared to Nyxoah's net margin of -443.16%. Jin Medical International's return on equity of 0.00% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-443.16%	-178.90%	-81.83%
Jin Medical International	N/A	N/A	N/A

Nyxoah currently has a consensus price target of $4.26, suggesting a potential upside of 220.45%. Given Nyxoah's stronger consensus rating and higher probable upside, research analysts clearly believe Nyxoah is more favorable than Jin Medical International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nyxoah has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Comparatively, Jin Medical International has a beta of 7.31, meaning that its share price is 631% more volatile than the broader market.

In the previous week, Nyxoah had 3 more articles in the media than Jin Medical International. MarketBeat recorded 3 mentions for Nyxoah and 0 mentions for Jin Medical International. Nyxoah's average media sentiment score of 0.00 equaled Jin Medical International'saverage media sentiment score.

Company	Overall Sentiment
Nyxoah	Neutral
Jin Medical International	Neutral

Jin Medical International has higher revenue and earnings than Nyxoah.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	4.55	-$101.92M	-$2.52	N/A
Jin Medical International	$20.69M	7.77	$1.19M	N/A	N/A

Summary

Jin Medical International beats Nyxoah on 7 of the 11 factors compared between the two stocks.

Get Nyxoah News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NYXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NYXH vs. The Competition

Export

Metric	Nyxoah	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$54.26M	$5.58B	$7.31B	$13.29B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	-0.53	25.26	274.08	25.69
Price / Sales	4.55	71.56	638.21	78.99
Price / Cash	N/A	33.02	77.80	52.76
Price / Book	0.93	5.78	10.47	6.32
Net Income	-$101.92M	$151.55M	$3.49B	$359.73M
7 Day Performance	-10.74%	-0.01%	-0.67%	0.17%
1 Month Performance	-17.90%	-3.53%	-3.17%	-3.27%
1 Year Performance	-72.23%	6.37%	15.14%	5.58%

Nyxoah Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NYXH Nyxoah	3.1639 of 5 stars	$1.33 -5.0%	$4.26 +220.5%	-72.6%	$54.26M	$11.33M	N/A	154
STIM Neuronetics	3.4622 of 5 stars	$2.80 -3.4%	$4.67 +66.7%	+4.7%	$221.35M	$149.16M	N/A	658
ELMD Electromed	2.3085 of 5 stars	$26.29 -0.4%	$43.75 +66.4%	+15.5%	$219.94M	$73.78M	35.05	197
PDEX Pro-Dex	3.7512 of 5 stars	$66.91 +0.5%	$74.00 +10.6%	+112.1%	$213.21M	$77.55M	16.20	206	Analyst Downgrade
PROF Profound Medical	2.5577 of 5 stars	$5.68 -2.2%	$11.50 +102.5%	+13.4%	$212.25M	$16.10M	N/A	162

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NYXH) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nyxoah (NYXH) Competitors